Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression

Journal of Biological Chemistry

Volumn 289, Issue 30, 2014, Pages 20543-20558

  Meng, X Wei ^a,b   Koh, Brian D ^a   Zhang, Jin San ^a   Flatten, Karen S ^a   Schneider, Paula A ^a   Billadeau, Daniel D ^a   Hess, Allan D ^c   Smith, B Douglas ^c   Karp, Judith E ^c   Kaufmann, Scott H ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; CELL CULTURE; CELL DEATH; CELL MEMBRANES; MONOCLONAL ANTIBODIES;

CELL SURFACE EXPRESSION; CHROMATIN IMMUNOPRECIPITATION; MYELOID LEUKEMIA; NATURAL KILLER CELLS; NON SMALL CELL LUNG CANCER; POLY(ADP-RIBOSE) POLYMERASE; SENSITIZED CELLS; SENSITIZING EFFECTS;

DISEASES;

ENZYME INHIBITOR; FAS ANTIGEN; FAS PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SP1 PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; K562 CELL LINE; METABOLISM; NEOPLASMS;

ANTIGENS, CD95; APOPTOSIS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RESPONSE ELEMENTS; SP1 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84905407213     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.549220     Document Type: Article

References (80)

1. Siegel, R., Naishadham, D., and Jemal, A. (2012) Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29
2. Ozören, N., and El-Deiry, W. S. (2003) Cell surface Death Receptor signaling in normal and cancer cells. Semin. Cancer Biol. 13, 135-147
3. Yang, A., Wilson, N. S., and Ashkenazi, A. (2010) Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr. Opin. Cell Biol. 22, 837-844
4. Wilson, N. S., Yang, A., Yang, B., Couto, S., Stern, H., Gogineni, A., Pitti, R., Marsters, S., Weimer, R. M., Singh, M., and Ashkenazi, A. (2012) Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell 22, 80-90
5. Taylor, R. C., Cullen, S. P., and Martin, S. J. (2008) Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell biology 9, 231-241
6. Falschlehner, C., Ganten, T. M., Koschny, R., Schaefer, U., and Walczak, H. (2009) TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv. Exp. Med. Biol. 647, 195-206
7. Wang, S. (2010) TRAIL: a sword for killing tumors. Curr. Med. Chem. 17, 3309-3317
8. Wang, G., Wang, X., Yu, H., Wei, S., Williams, N., Holmes, D. L., Halfmann, R., Naidoo, J., Wang, L., Li, L., Chen, S., Harran, P., Lei, X., and Wang, X. (2013) Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat. Chem. Biol. 9, 84-89
9. Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68, 383-424
10. Creagh, E. M., and Martin, S. J. (2001) Caspases: cellular demolition experts. Biochem. Soc. Trans. 29, 696-702
11. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. (1999) Safety and antitumor activity of recombinant soluble apo2 ligand. J. Clin. Invest. 104, 155-162
12. Ashworth, A. (2008) A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790
13. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., and Poirier, G. G. (2010) PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293-301
14. Curtin, N. J. (2012) DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 12, 801-817
15. Plummer, R. (2012) PARP inhibitors. Clin. Adv. Hematol. Oncol. 10, 322-323
16. Hilton, J. F., Hadfield, M. J., Tran, M. T., and Shapiro, G. I. (2013) Poly-(ADP-ribose) polymerase inhibitors as cancer therapy. Front. Biosci. 18, 1392-1406
17. Amé, J. C., Spenlehauer, C., and de Murcia, G. (2004) The PARP superfamily. Bioessays 26, 882-893
18. Hassa, P. O., and Hottiger, M. O. (2008) The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci. 13, 3046-3082
19. Gagné, J. P., Pic, E., Isabelle, M., Krietsch, J., Ethier, C., Paquet, E., Kelly, I., Boutin, M., Moon, K. M., Foster, L. J., and Poirier, G. G. (2012) Quantitative proteomics profiling of the poly (ADP-ribose)-related response to genotoxic stress. Nucleic acids Res. 40, 7788-7805
20. Jungmichel, S., Rosenthal, F., Altmeyer, M., Lukas, J., Hottiger, M. O., and Nielsen, M. L. (2013) Proteome-wide identification of poly (ADP-Ribosyl) ation targets in different genotoxic stress responses. Mol. Cell 52, 272-285
21. de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., Walztinger, C., Chambon, P., and de Murcia, G. (1997) Requirement of poly (ADPribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. U. S. A. 94, 7303-7307
22. Trucco, C., Oliver, F. J., de Murcia, G., and Ménissier-de Murcia, J. (1998) DNA repair defect in poly (ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res. 26, 2644-2649
23. Javle, M., and Curtin, N. J. (2011) The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer 105, 1114-1122
24. De Vos, M., Schreiber, V., and Dantzer, F. (2012) The diverse roles and clinical relevance of PARPs inDNAdamage repair: current state of the art. Biochem. Pharmacol. 84, 137-146
25. Krishnakumar, R., and Kraus, W. L. (2010) PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol. Cell 39, 736-749
26. Kraus, W. L., and Hottiger, M. O. (2013) PARP-1 and gene regulation: progress and puzzles. Mol. Aspects Med. 34, 1109-1123
27. Amé, J. C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Höger, T., Ménissier-de Murcia, J., and de Murcia, G. (1999) PARP-2, a novel mammalian DNA damage-dependent poly (ADP-ribose) polymerase. J. Biol. Chem. 274, 17860-17868
28. Schreiber, V., Amé, J. C., Dollé, P., Schultz, I., Rinaldi, B., Fraulob, V., Ménissier-de Murcia, J., and de Murcia, G. (2002) Poly (ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. 277, 23028-23036
29. Yélamos, J., Schreiber, V., and Dantzer, F. (2008) Toward specific functions of poly (ADP-ribose) polymerase-2. Trends Mol. Med. 14, 169-178
30. Lee, S. H., Meng, X. W., Flatten, K. S., Loegering, D. A., and Kaufmann, S. H. (2013) Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ. 20, 64-76
31. Mesa, R. A., Loegering, D., Powell, H. L., Flatten, K., Arlander, S. J., Dai, N. T., Heldebrant, M. P., Vroman, B. T., Smith, B. D., Karp, J. E., Eyck, C. J., Erlichman, C., Kaufmann, S. H., and Karnitz, L. M. (2005) Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106, 318-327
32. Caserta, T. M., Smith, A. N., Gultice, A. D., Reedy, M. A., and Brown, T. L. (2003) Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8, 345-352
33. Meng, X. W., Peterson, K. L., Dai, H., Schneider, P., Lee, S. H., Zhang, J. S., Koenig, A., Bronk, S., Billadeau, D. D., Gores, G. J., and Kaufmann, S. H. (2011) High cell surface death receptor expression determines type I versus type II signaling. J. Biol. Chem. 286, 35823-35833
34. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85
35. Kaufmann, S. H., Okret, S., Wikström, A.-C., Gustafsson, J.-Å., and Shaper, J. H. (1986) Binding of the glucocorticoid receptor to the rat liver nuclear matrix: the role of disulfide bond formation. J. Biol. Chem. 261, 11962-11967
36. Kaufmann, S. H. (2001) Reutilization of immunoblots after chemiluminescent detection. Anal. Biochem. 296, 283-286
37. Meng, X. W., Heldebrant, M. P., and Kaufmann, S. H. (2002) Phorbol-12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting FADD recruitment. J. Biol. Chem. 277, 3776-3783
38. Meng, X. W., Heldebrant, M. P., Flatten, K. S., Loegering, D. A., Dai, H., Schneider, P. A., Gomez, T. S., Peterson K. L., Trushin, S. A., Hess, A. D., Smith, B. D., Karp, J. E., Billadeau, D. D., and Kaufmann, S. H. (2010) Protein kinase C in modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. J. Biol. Chem. 285, 888-902
39. Zhang, J. S., Koenig, A., Harrison, A., Ugolkov, A. V., Fernandez-Zapico, M. E., Couch, F. J., and Billadeau, D. D. (2011) Mutant K-Ras increases GSK-3' gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. Oncogene 30, 3705-3715
40. Chan, H., Bartos, D. P., and Owen-Schaub, L. B. (1999) Activation-dependent transcriptional regulation of the human Fas promoter requires NF-κB p50-p65 recruitment. Mol. Cell. Biol. 19, 2098-2108
41. Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., and Bloomfield, C. D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937-951
42. Eaves, C., and Lambie, K. (1995) Atlas of human hematopoietic colonies, StemCell Technologies Inc., Vancouver, BC, Canada
43. Matthews, D. E., and Farewell, V. T. (eds). (1988) Using and Understanding Medical Statistics, pp. 178-181, Karger, Basel, Switzerland
44. Chou, T.-C., and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55
45. Berenbaum, M. C. (1989) What is synergy? Pharmacol. Rev. 41, 93-141
46. Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., Ferguson, D. C., Ghoreishi-Haack, N. S., Grimm, D. R., Guan, R., Han, E. K., Holley-Shanks, R. R., Hristov, B., Idler, K. B., Jarvis, K., Johnson, E. F., Kleinberg, L. R., Klinghofer, V., Lasko, L. M., Liu, X., Marsh, K. C., McGonigal, T. P., Meulbroek, J. A., Olson, A. M., Palma, J. P., Rodriguez, L. E., Shi, Y., Stavropoulos, J. A., Tsurutani, A. C., Zhu, G. D., Rosenberg, S. H., Giranda, V. L., and Frost, D. J. (2007) ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728-2737
47. Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H., and de Bono, J. S. (2009) Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134
48. Bowman, K. J., Newell, D. R., Calvert, A. H., and Curtin, N. J. (2001) Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer 84, 106-112
49. Huehls, A. M., Wagner, J. M., Huntoon, C. J., Geng, L., Erlichman, C., Patel, A. G., Kaufmann, S. H., and Karnitz, L. M. (2011) Poly (ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res. 71, 4944-4954
50. Patel, A. G., Flatten, K. S., Schneider, P. A., Dai, N. T., McDonald, J. S., Poirier, G. G., and Kaufmann, S. H. (2012) Enhanced killing of cancer cells by poly (ADP-ribose) polymerase inhibitors and topoisomerase inhibitors reflects poisoning of both enzymes. J. Biol. Chem. 287, 4198-4210
51. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) FLICE, a novel FADDhomologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827
52. Slee, E. A., Harte, M. T., Kluck, R. M., Wolf, B. B., Casiano, C. A., Newmeyer, D. D., Wang, H.-G., Reed, J. C., Nicholson, D. W., Alnemri, E. S., Green, D. R., and Martin, S. J. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 144, 281-292
53. Yuan, K., Sun, Y., Zhou, T., McDonald, J., and Chen, Y. (2013) PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin. Cancer Res. 19, 4750-4759
54. Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A., Thorsell, A. G., Pol, E., Frostell, Å., Ekblad, T., Öncü, D., Kull, B., Robertson, G. M., Pellicciari, R., Schüler, H., and Weigelt, J. (2012) Familywide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat. Biotechnol. 30, 283-288
55. Yoshida, T., Maeda, A., Tani, N., and Sakai, T. (2001) Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 507, 381-385
56. Higuchi, H., Grambihler, A., Canbay, A., Bronk, S. F., and Gores, G. J. (2004) Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun. N-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem. 279, 51-60
57. Robinson, S. I., Nelkin, B. D., and Vogelstein, B. (1982) The ovalbumin gene is associated with the nuclear matrix of chicken oviduct cells. Cell 28, 99-106
58. Robinson, S. I., Small, D., Idzerda, R., McKnight, G. S., and Vogelstein, B. (1983) The association of transcriptionally active genes with the nuclear matrix of the chicken oviduct. Nucleic Acids Res. 11, 5113-5130
59. Izeradjene, K., Douglas, L., Delaney, A. B., and Houghton, J. A. (2004) Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex. Cancer Res. 64, 8036-8044
60. Meng, X. W., Lee, S. H., Dai, H., Loegering, D., Yu, C., Flatten, K., Schneider, P., Dai, N. T., Kumar, S. K., Smith, B. D., Karp, J. E., Adjei, A. A., and Kaufmann, S. H. (2007) Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 282, 29831-29846
61. Rosato, R. R., Almenara, J. A., Coe, S., and Grant, S. (2007) The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 67, 9490-9500
62. Ravi, R., Jain, A. J., Schulick, R. D., Pham, V., Prouser, T. S., Allen, H., Mayer, E. G., Yu, H., Pardoll, D. M., Ashkenazi, A., and Bedi, A. (2004) Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 64, 9105-9114
63. Naka, T., Sugamura, K., Hylander, B. L., Widmer, M. B., Rustum, Y. M., and Repasky, E. A. (2002) Effects of tumor necrosis factor-related apoptosisinducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62, 5800-5806
64. Wang, S., and El-Deiry, W. S. (2003) Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. U. S. A. 100, 15095-15100
65. Vousden, K. H., and Lu, X. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604
66. Bi, S., Hughes, T., Bungey, J., Chase, A., de Fabritiis, P., and Goldman, J. M. (1992) p53 in chronic myeloid leukemia cell lines. Leukemia 6, 839-842
67. Feinstein, E., Gale, R. P., Reed, J., and Canaani, E. (1992) Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 7, 1853-1857
68. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311
69. el-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., and Wang, Y. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169-1174
70. Sun, J. M., Penner, C. G., and Davie, J. R. (1993) Repression of histone H5 gene expression in chicken mature erythrocytes is correlated with reduced DNA-binding activities of transcription factors Sp1 and GATA-1. FEBS Lett. 331, 141-144
71. Davie, J. R., He, S., Li, L., Sekhavat, A., Espino, P., Drobic, B., Dunn, K. L., Sun, J. M., Chen, H. Y., Yu, J., Pritchard, S., and Wang, X. (2008) Nuclear organization and chromatin dynamics: Sp1, Sp3 and histone deacetylases. Adv. Enzyme Regul. 48, 189-208
72. Satoh, M. S., and Lindahl, T. (1992) Role of poly (ADP-ribose) formation in DNA repair. Nature 356, 356-358
73. Liu, X., Han, E. K., Anderson, M., Shi, Y., Semizarov, D., Wang, G., McGonigal, T., Roberts, L., Lasko, L., Palma, J., Zhu, G. D., Penning, T., Rosenberg, S., Giranda, V. L., Luo, Y., Leverson, J., Johnson, E. F., and Shoemaker, A. R. (2009) Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol. Cancer Res. 7, 1686-1692
74. Murai, J., Huang, S. Y., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., and Pommier, Y. (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588-5599
75. Smith, M. A., and Houghton, P. (2013) A proposal regarding reporting of in vitro testing results. Clin. Cancer Res. 19, 2828-2833
76. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. (1993) Lethal effect of the anti-fas antibody in mice. Nature 364, 806-809
77. Bajaj, M., and Heath, E. I. (2011) Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults. Expert Opin. Biol. Ther. 11, 1519-1524
78. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., Kinders, R., Wang, L., Parchment, R. E., Carter, J., Stotler, H., Rubinstein, L., Hollingshead, M., Melillo, G., Pommier, Y., Bonner, W., Tomaszewski, J. E., and Doroshow, J. H. (2011) Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 71, 5626-5634
79. Gilliland, D. G., and Griffin, J. D. (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100, 1532-1542
80. Patel, A. G., Sarkaria, J. N., and Kaufmann, S. H. (2011) Nonhomologous end joining drives poly (ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl. Acad. Sci. U. S. A. 108, 3406-3411